🔗 Share this article

As the US continues making unprecedented adjustments to its vaccination schedules, one figure has surfaced in a surprising turn: Høeg, an American of Danish descent physician and epidemiologist who first made her name by expressing skepticism about coronavirus vaccinations in the pandemic and has zeroed in on alleged deaths following Covid immunization in her short time at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Immunization Program

Health officials had intended to announce radical changes to the childhood vaccine schedule earlier this month, aligning the US with Denmark’s vaccine program, it is understood – a major change that would put the US out of alignment with many the world with little proof for benefit. The announcement has been pushed back until the new year.

Instead of the director of the vaccine center, Tracy Beth Høeg is scheduled to present at the meeting. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth appointee to lead the center this calendar year.

Consolidating Power at the FDA

This interim role might represent a strengthened alliance between the drug and biologics divisions as Høeg and Prasad strengthen their influence at the FDA – and it signals a greater focus upon dismantling already-approved immunizations at the FDA.

Høeg has frequently advocated for ending specific childhood shot schedules in the US in order to be more similar to the Danish model, a society with nationalized medicine and a citizenry roughly the population of the state of Wisconsin.

In her initial public appearances, she has continued to focus on immunizations – typically the domain of Prasad, head of the FDA’s vaccine center – rather than medication approval.

Questions Over Expertise

Høeg has no obvious experience in pharmaceutical research, oversight or leadership, which has been customary for former heads of the CBER. She has been employed at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for leading the CDER, stated Jonathan Howard. “She’s never run a clinical trial. She is not versed in running a major agency. She has no expertise in drug approvals.”

Past directors of the center would “understand laws and regulations and the underlying principles of medication creation”, noted Dr. Janet Woodcock. “Objectively, she lacks the type of experience that previous people who headed CBER have had.”

The drug center has an vast workload at the agency, Woodcock emphasized.

“The public just focuses on the new drug program, but the generic drug division clears thousands of generic medications. There’s a biosimilars division, non-prescription drug unit and more, and every single one have to be supervised,” Woodcock said. “The area you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Furthermore, a major management element to the position, which oversees more than 5,000 staff members. “It is a enormous leadership role, if you perform it correctly,” Woodcock concluded.

Response and Contentious Policies

Regarding questions about Høeg’s credentials and whether this assignment represents greater collaboration among agency officials on vaccines, a representative stated that the “concerns rely on incorrect presumptions”.

“This background matches the responsibilities of her job,” the spokesperson said, pointing to the time Høeg spent counseling the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Dr. Høeg assumes responsibility for the agency head's recently launched priority voucher program, a disputed rapid drug-approval program that apparently troubled her preceding directors. “How are these medications being selected for this voucher program? Who is making the decisions?” Dr. Howard said. “There’s a lot of secrecy occurring at the regulatory body right now.”

Overall, he said, “the Food and Drug Administration looks to be trending towards laxer regulations of all drugs, aside from shots.”

Established Past Work on Vaccines

With vaccines, Dr. Høeg has a more established, if problematic, history, Howard said. She released a analysis using unverified public submissions to estimate the rate of heart inflammation following COVID-19 immunization. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccinations are more dangerous than they are.

Among her “wish list” for the new administration included revising regulations for recently developed shots and ending “optional” immunizations, she said after the election on a online show. At the agency, Høeg has allegedly proposed preventing adolescent males from receiving COVID-19 vaccinations.

“She’s an all-around ideologue who begins with her conclusions and tailors the evidence to accommodate the science in a very disingenuous, untruthful way,” Howard stated.

Taking Control and a “Revenge Tour”

Dr. Høeg joined other skeptics, {like|